What the business is, and whether it's a good one at a fair price.
Manufactures pharmaceutical active ingredients (APIs), intermediates and nutritional premixes, with vitamin D3 driving 87% of turnover. Operations are organised around three core verticals disclosed in the FY26 investor presentation: a Human Nutrition line built on vitamin D3 (Rs 293 crore in FY26, up 28% year-on-year), an Animal Nutrition business (Rs 109 crore, up 32%), and a smaller Green Chemistry unit whose sales more than doubled to Rs 16 crore, alongside a residual Property segment. The company exports 58% of output to around 60 countries and serves more than 400 customers. Manufacturing quality systems are certified to EU-GMP, USFDA, WHO-GMP and ISO standards. In July 2026 it received FSSAI approval for its plant-source vitamin D3 (VITADEE Green) for use in Indian fortified foods and supplements. The cost structure is led by materials (28.3% of revenue) and other operating expenses (28.8%), with employee costs at 15.7% and depreciation at 4.1%; capex ran at 5.8% of revenue. FY26 consolidated revenue was Rs 548 crore and standalone revenue Rs 525 crore, with EBITDA margin around 22-25%.
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
How has the market priced it — with filings on the timeline?
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
How does it stack up on valuation, returns and growth?
Loading peers…
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Answered from FERMENTA BIOTECH LTD.'s filed financials and exchange disclosures
FERMENTA BIOTECH LTD. is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol FERMENTA.
Yes. Over the trailing twelve months FERMENTA BIOTECH LTD. reported a net profit of ₹58 Cr on revenue of ₹511 Cr.
Yes. The dividend yield is 0.54% at the current price. It paid out 10% of its profit as dividend in FY26.
No. Debt stands at 0.27× equity, and it carries net debt of ₹77 Cr. That is lower than 33% of its 171 Pharmaceuticals peers.
On trailing P/E, FERMENTA BIOTECH LTD. ranks 67 of 169 in Pharmaceuticals — cheaper than 61% of them, against an industry median of 28.9×. This is a position, not a valuation judgement.
On a typical session FERMENTA BIOTECH LTD. moves 2.07% — that is the median absolute close-to-close move across its last 100 trading days. Announcement days are routinely larger.
Every NSE and BSE filing by FERMENTA BIOTECH LTD. appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.
